Alignment Healthcare Faces Analyst Downgrades and Outlook Updates
Alignment Healthcare received multiple analyst price target cuts and a downgrade following updates on its 2027 revenue growth outlook and 2028 Medicare Advantage plan star ratings.
Stocks · News reference
Alignment Health and functional soda brand OLIPOP conducted a survey of Medicare Advantage members to evaluate the impact of providing healthier beverage alternatives on wellness perceptions.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alignment Healthcare received multiple analyst price target cuts and a downgrade following updates on its 2027 revenue growth outlook and 2028 Medicare Advantage plan star ratings.
TD Cowen has maintained its 'Buy' rating on Alignment Healthcare while reducing its price target from $12 to $10.
Law firm Glancy Prongay Wolke & Rotter LLP is investigating Alignment Healthcare, Inc. for potential securities fraud following a whistleblower lawsuit alleging the company manipulated finances by misclassifying $8-10 million in operating expenses as capital expenditures to artificially inflate adjusted EBITDA. The disclosure on July 8, 2026 caused the stock to drop 16.7% to $20.03 per share. Investors who suffered losses may be eligible to pursue claims.
U.S. futures fell as Pinterest missed Q3 estimates and cut guidance; Intel, ATEC, Reddit, Roblox and others slid sharply premarket.